Patents by Inventor Thomas Jorg Mehrling

Thomas Jorg Mehrling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination comprising a glucocorticoid and EDO-S101
    Patent number: 10744120
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: August 18, 2020
    Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • COMPOUNDS FOR TREATING TNBC
    Publication number: 20200230109
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC)to a patient in need thereof.
    Type: Application
    Filed: June 13, 2018
    Publication date: July 23, 2020
    Applicant: PURDUE PHARMA L.P.
    Inventor: Thomas Jorg MEHRLING
  • TINOSTAMUSTINE FOR USE IN TREATING SARCOMA
    Publication number: 20200113870
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof.
    Type: Application
    Filed: June 13, 2018
    Publication date: April 16, 2020
    Applicant: PURDUE PHARMA L.P.
    Inventor: Thomas Jorg MEHRLING
  • TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA
    Publication number: 20200113871
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Application
    Filed: June 13, 2018
    Publication date: April 16, 2020
    Applicant: PURDUE PHARMA L.P.
    Inventors: Thomas Jorg MEHRLING, Marco HERLING
  • Pharmaceutical combinations for treating cancer
    Patent number: 10406138
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 10, 2019
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
    Publication number: 20180369204
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: May 21, 2018
    Publication date: December 27, 2018
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • Pharmaceutical combination comprising a class III receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule EDO-S101 together with its use in the treatment of cancer
    Patent number: 9993482
    Abstract: The present invention is directed to a combination comprising a class III receptor tyrosine kinase inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: June 12, 2018
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventor: Thomas Jorg Mehrling
  • COMBINATION COMPRISING A GLUCOCORTICOID AND EDO-S101
    Publication number: 20170296513
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: May 26, 2015
    Publication date: October 19, 2017
    Applicant: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
    Publication number: 20170151218
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: May 26, 2015
    Publication date: June 1, 2017
    Applicant: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • PHARMACEUTICAL COMBINATION COMPRISING A CLASS III RECEPTOR TYROSINE KINASE INHIBITOR AND THE ALKYLATING HISTONE-DEACETYLASE INHIBITOR FUSION MOLECULE EDO-S101 TOGETHER WITH ITS USE IN THE TREATMENT OF CANCER
    Publication number: 20170095482
    Abstract: The present invention is directed to a combination comprising a class III receptor tyrosine kinase inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: May 26, 2015
    Publication date: April 6, 2017
    Inventor: Thomas Jorg Mehrling